BTK and autoimmune thrombocytopenic purpura: Combined results from four publications including 574 adult ITP patients showed no significant disparity in the overall incidence of upper respiratory infection between individuals administered SYK and/or BTK inhibitors and those given a placebo (RR 1.42; 95%CI: 0.83 – 2.41, p=0.19, I2 = 31%, random-effect model) (Table 3).